Journal Watch · Frontiers in Immunology · 2026

Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.

As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.

Nimskov-Peen EC, Müller K, Kielsen K, Marquart HVFrontiers in Immunology3 min readPharma relevance 30/100

DOI: 10.3389/fimmu.2026.1923247PMID: 42819209Study type: research study

TL;DR

As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.

Key findings

  • As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.

Numbers at a glance (from the abstract)

0.16%0.99%2.25%p<0.008p<0.05p<0.017

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

In multivariable Cox proportional hazards models, low proportions of total B cells, BCPI, and BCPII at month +2 and month +3 were independent risk factors for cGvHD (HR=6.9-14.1, all p<0.017). At +2 months after HSCT, ROC analysis for predicting cGvHD with cut-off values of 0.16% (BCPI) and 0.99% (BCPII), yielded a sensitivity of 1.0 and a specificity of 0.69, while a cut-off value of 2.25% for total B cells resulted in a sensitivity of 0.90 and a specificity of 0.69.<h4>Discussion</h4>These findings support previous evidence of disturbed B-cell reconstitution in cGvHD and suggest that phenotypic monitoring of BM B cells following pediatric HSCT may facilitate early cGvHD risk stratification.

Full abstract (original)

Background: <h4>Introduction</h4>Allogeneic hematopoietic stem cell transplantation (HSCT) in children remains challenged by chronic graft-versus-host-disease (cGvHD), significantly affecting morbidity and survival. While aberrant peripheral B-cell reconstitution has been implicated in cGvHD, B-cell development in the bone marrow (BM) remains less explored.<h4>Method</h4>We investigated the B-cell reconstitution in BM samples and its potential to predict cGvHD in 76 children undergoing HSCT for acute leukemia (2010-2021) by blinded immunophenotypic analysis.<h4>Results</h4>Children developing cGvHD exhibited delayed B-cell reconstitution in the BM with significantly lower proportions of total B cells and early B-cell precursors (BCP) I and II from +2 months to +9 months post-HSCT (all p<0.008) and reduced BCPIII and mature B cells at later time points compared to those without cGvHD (all p<0.05).

What they did: In multivariable Cox proportional hazards models, low proportions of total B cells, BCPI, and BCPII at month +2 and month +3 were independent risk factors for cGvHD (HR=6.9-14.1, all p<0.017). At +2 months after HSCT, ROC analysis for predicting cGvHD with cut-off values of 0.16% (BCPI) and 0.99% (BCPII), yielded a sensitivity of 1.0 and a specificity of 0.69, while a cut-off value of 2.25% for total B cells resulted in a sensitivity of 0.90 and a specificity of 0.69.<h4>Discussion</h4>These findings support previous evidence of disturbed B-cell reconstitution in cGvHD and suggest that phenotypic monitoring of BM B cells following pediatric HSCT may facilitate early cGvHD risk stratification.

Results & conclusions: As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1923247 · PubMed 42819209.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.

What type of study is this?

It is a research study, published in Frontiers in Immunology in 2026. In multivariable Cox proportional hazards models, low proportions of total B cells, BCPI, and BCPII at month +2 and month +3 were independent risk factors for cGvHD (HR=6.9-14.1, all p<0.017).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1923247. PubMed ID: 42819209. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Nimskov-Peen EC, Müller K, Kielsen K, Marquart HV. Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1923247.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/delayed-b-cell-reconstitution-in-the-bone-marrow-precedes-the-developmen-923247/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides